NO20051407D0 - Prolinderivater med affinitet for kalsiumkanal alfa-2-delta subenheten - Google Patents

Prolinderivater med affinitet for kalsiumkanal alfa-2-delta subenheten

Info

Publication number
NO20051407D0
NO20051407D0 NO20051407A NO20051407A NO20051407D0 NO 20051407 D0 NO20051407 D0 NO 20051407D0 NO 20051407 A NO20051407 A NO 20051407A NO 20051407 A NO20051407 A NO 20051407A NO 20051407 D0 NO20051407 D0 NO 20051407D0
Authority
NO
Norway
Prior art keywords
affinity
calcium channel
channel alpha
proline derivatives
delta subunit
Prior art date
Application number
NO20051407A
Other languages
English (en)
Other versions
NO20051407L (no
NO330496B1 (no
Inventor
David James Rawson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20051407D0 publication Critical patent/NO20051407D0/no
Publication of NO20051407L publication Critical patent/NO20051407L/no
Publication of NO330496B1 publication Critical patent/NO330496B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20051407A 2002-10-31 2005-03-17 Anvendelse av prolinderivater, farmasoytisk sammensetning samt prolinderivater NO330496B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0225379.7A GB0225379D0 (en) 2002-10-31 2002-10-31 Therapeutic proline derivatives
PCT/IB2003/004697 WO2004039367A1 (en) 2002-10-31 2003-10-22 Proline derivatives having affinity for the calcium channel alpha-2-delta subunit

Publications (3)

Publication Number Publication Date
NO20051407D0 true NO20051407D0 (no) 2005-03-17
NO20051407L NO20051407L (no) 2005-07-26
NO330496B1 NO330496B1 (no) 2011-05-02

Family

ID=9946940

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051407A NO330496B1 (no) 2002-10-31 2005-03-17 Anvendelse av prolinderivater, farmasoytisk sammensetning samt prolinderivater

Country Status (39)

Country Link
EP (1) EP1558246B1 (no)
JP (2) JP3940416B2 (no)
KR (2) KR20070046213A (no)
CN (1) CN100418525C (no)
AP (1) AP2005003295A0 (no)
AR (1) AR041865A1 (no)
AT (1) ATE468116T1 (no)
AU (1) AU2003269411B2 (no)
BR (1) BR0315839A (no)
CA (1) CA2499698C (no)
CO (1) CO5550430A2 (no)
CR (1) CR7802A (no)
DE (1) DE60332646D1 (no)
DK (1) DK1558246T3 (no)
EA (1) EA009767B1 (no)
EC (1) ECSP055769A (no)
ES (1) ES2343624T3 (no)
GB (1) GB0225379D0 (no)
GE (1) GEP20074127B (no)
GT (1) GT200300234A (no)
HK (1) HK1081441A1 (no)
HR (1) HRP20050351A2 (no)
IL (4) IL167799A (no)
IS (1) IS7754A (no)
MA (1) MA27481A1 (no)
MX (1) MXPA05004662A (no)
NL (1) NL1024677C2 (no)
NO (1) NO330496B1 (no)
OA (1) OA12954A (no)
PA (1) PA8587201A1 (no)
PE (1) PE20040553A1 (no)
PL (1) PL376703A1 (no)
RS (1) RS20050333A (no)
TN (1) TNSN05122A1 (no)
TW (2) TW200633699A (no)
UA (1) UA81437C2 (no)
UY (1) UY28043A1 (no)
WO (1) WO2004039367A1 (no)
ZA (1) ZA200502305B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2005097741A1 (en) * 2004-04-05 2005-10-20 Pfizer Limited Process for the recrystallisation of proline derivates
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
WO2007142028A1 (ja) 2006-06-06 2007-12-13 Gifu University 神経因性疼痛を抑制するピロリジン類縁体及びその製造方法
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP2016523266A (ja) 2013-06-26 2016-08-08 浙江九洲▲藥▼▲業▼股▲ふぇん▼有限公司 ピロリジン−２−カルボン酸誘導体の調製方法
WO2015003723A1 (en) * 2013-07-12 2015-01-15 Københavns Universitet Substituted 4-proline derivatives as iglur antagonists
CN104418785A (zh) * 2013-09-05 2015-03-18 浙江九洲药业股份有限公司 一种药物中间体的制备方法
CN104829513B (zh) * 2014-02-11 2019-02-19 浙江九洲药业股份有限公司 一种2-羧基-4-甲氧基甲基吡咯烷衍生物的制备方法
CN104844495A (zh) * 2015-06-05 2015-08-19 武汉理工大学 一种(2s,4s)-4-苯硫基-l-脯氨酸盐酸盐的合成方法
WO2020120606A1 (en) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions
TW202026281A (zh) * 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
EP3904339A1 (en) * 2020-04-28 2021-11-03 Esteve Pharmaceuticals, S.A. Alkylaminoproline derivatives as alfa-2-delta-1 blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1144930A (en) * 1978-08-11 1983-04-19 Miguel A. Ondetti Mercaptoacyl derivatives of substituted prolines
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
US4311705A (en) * 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
ZA817601B (en) * 1980-11-24 1982-10-27 Squibb & Sons Inc Carboxyalkyl amino acid derivatives of various substituted prolines
AU1873992A (en) * 1991-04-19 1992-11-17 Nova Technology Limited Partnership Bradykinin antagonist peptides
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
DE69734885T2 (de) * 1996-08-02 2006-08-24 Elan Pharmaceuticals, Inc., South San Francisco Klasse e-spannungsabhängiger calciumkanal-antagonist und verfahren
JP3196106B2 (ja) * 1997-03-27 2001-08-06 参天製薬株式会社 ロイコトリエンａ４ヒドロラーゼ阻害剤
WO1999061424A1 (en) * 1998-05-26 1999-12-02 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives

Also Published As

Publication number Publication date
CO5550430A2 (es) 2005-08-31
NL1024677A1 (nl) 2004-05-06
NO20051407L (no) 2005-07-26
TW200416030A (en) 2004-09-01
AR041865A1 (es) 2005-06-01
KR100750782B1 (ko) 2007-08-20
JP2006516115A (ja) 2006-06-22
CN1711081A (zh) 2005-12-21
DE60332646D1 (de) 2010-07-01
MA27481A1 (fr) 2005-08-01
NO330496B1 (no) 2011-05-02
CN100418525C (zh) 2008-09-17
UA81437C2 (en) 2008-01-10
AU2003269411A1 (en) 2004-05-25
PE20040553A1 (es) 2004-08-28
JP3940416B2 (ja) 2007-07-04
NL1024677C2 (nl) 2005-07-04
PA8587201A1 (es) 2004-05-26
IL201967A (en) 2011-06-30
CR7802A (es) 2007-10-23
TNSN05122A1 (fr) 2007-05-14
ECSP055769A (es) 2005-08-11
GT200300234A (es) 2004-06-23
CA2499698C (en) 2009-01-20
ATE468116T1 (de) 2010-06-15
EP1558246B1 (en) 2010-05-19
IL201965A (en) 2011-03-31
WO2004039367A1 (en) 2004-05-13
UY28043A1 (es) 2004-05-31
GB0225379D0 (en) 2002-12-11
RS20050333A (en) 2007-06-04
EA009767B1 (ru) 2008-04-28
JP2006328078A (ja) 2006-12-07
KR20050065646A (ko) 2005-06-29
MXPA05004662A (es) 2005-06-08
KR20070046213A (ko) 2007-05-02
GEP20074127B (en) 2007-06-11
DK1558246T3 (da) 2010-08-09
ES2343624T3 (es) 2010-08-05
EP1558246A1 (en) 2005-08-03
IS7754A (is) 2005-03-17
EA200500581A1 (ru) 2005-12-29
OA12954A (en) 2006-10-13
HK1081441A1 (en) 2006-05-19
HRP20050351A2 (en) 2005-10-31
CA2499698A1 (en) 2004-05-13
PL376703A1 (pl) 2006-01-09
IL201966A (en) 2011-06-30
ZA200502305B (en) 2006-11-29
TW200633699A (en) 2006-10-01
JP4555263B2 (ja) 2010-09-29
BR0315839A (pt) 2005-09-27
AP2005003295A0 (en) 2005-06-30
AU2003269411B2 (en) 2009-06-18
IL167799A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
NO20051407D0 (no) Prolinderivater med affinitet for kalsiumkanal alfa-2-delta subenheten
DK1553929T3 (da) Sammensætning med kontrolleret frigivelse.
DE50307455D1 (de) Einstellsystem
IS7806A (is) Ónæmisvaldandi samsetning
DE10393374D2 (de) Zusammensetzung
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
SE0500163L (sv) Sammansättning
DE60305578D1 (de) T-mutter
DE50302630D1 (de) Verstellantrieb
DK1561472T3 (da) Faststofsammensætning
DE602004024386D1 (de) Schwefelhaltige naphthoylimidderivate
FI20020258A (fi) Kiristyselin
BR0301996B1 (pt) transmissão
FI20031042A0 (fi) Puristusmekanismi
NO20043489L (no) Sammensetning for inhalering
EP1804796A4 (en) AMINO-SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES
AR041234A1 (es) Rastrillo de labranza
DE60200289D1 (de) Übergangsanpassung
GB0217656D0 (en) Adjustable clip
NO20024377D0 (no) Kork med ventilering
AU2003301258A8 (en) Calcium channel agonists for psychotherapeutic use
DK1216704T3 (da) Valproatsammensætning med styret frigörelse
FI20021724A (fi) Kiristyselin
PL114312U1 (en) Tensioning joint
ATE542125T1 (de) Homing-verfahren

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees